- IBDoc® Patient Support
Treatment decisions often have to be made without the benefit of the calprotectin result in acute situations as laboratory results can often take a week or more to come through. Enabling a point of care solution with a rapid quantitative result can help triage limited resources and support immediate treatment decisions.
The Quantum Blue testing system combines the ease and speed of lateral flow technology with full quantitation by means of a small bench top reading device.
The Quantum Blue reader analyses colorimetric tests using camera technology and is designed for use with the BÜHLMANN lateral flow cartridges for the quantitative determination of calprotectin from faeces and serum, and for rapid drug & antibody testing for infliximab and adalimumab. The compact, bench top device is ideal for point-of-care, clinic or low throughput laboratory settings for screening and monitoring of patients.
The Quantum Blue reader can be used with a number of different assays to give quantitative results in a time frame that can impact the clinical decision.
Quantum Blue® fCAL is a rapid, quantitative Calprotectin testing platform for fast turn-around or lower throughput requirements.
If your Calprotectin test request number is too low to achieve a reasonable turn-around time using an ELISA method, or you require rapid results, Quantum Blue® provides a comprehensive, cost effective Calprotectin testing platform. Quantum Blue® can be used in either the clinic or laboratory setting.
Quantum Blue® sCAL (LF-MRP25) is a quantitative test designed to determine the level of calprotectin in serum and is used as a surrogate marker for the presence of elevated polymorphonuclear cells. The test has been demonstrated to be useful in:
Helping to Manage Juvenile Idiopathic Arthritis
Great Ormond Street Hospital User Report – Serum Calprotectin Monitoring
The BÜHLMANN Quantum Blue® Therapeutic Drug Monitoring assays are the first rapid tests to measure Infliximab and Adalimumab trough level in patient’s serum, allowing timely decision making for dose adjustments before the next dose.
|Quantum Blue anti-TNFα Drug Monitoring|
|Product Code||Description||Pack Size|
|LF-TLIF25||Quantum Blue® Infliximab||25 Tests|
|LF-TLIF10||Quantum Blue® Infliximab||10 Tests|
|LF-TLAD25||Quantum Blue® Adalimumab||25 Tests|
|LF-TLAD10||Quantum Blue® Adalimumab||10 Tests|
|LF-ADIF25||Quantum Blue® Anti-infliximab Antibody||25 Tests|
|LF-ADIF10||Quantum Blue® Anti-infliximab Antibody||10 Tests|
|LF-ADAD25||Quantum Blue® Anti-adalimumab Antibody||25 Tests|
|LF-ADAD10||Quantum Blue® Anti-adalimumab Antibody||10 Tests|